Loading people...
David Malek is a Venture Partner at Pivotal bioVenture Partners based in San Francisco, California. In this capacity, he focuses on life sciences investments and currently serves on the boards of Encodia, aptihealth, and Braveheart Bio, where he is also a co-founder. Previously, he served as Chief Business Officer at BioLineRx, where he helped raise over $100 million and established strategic partnerships with Novartis, Roche, and Merck. His corporate development background includes prior executive positions at OncXerna Therapeutics, Halozyme Therapeutics, and Sanofi, where he managed oncology business development and marketing initiatives. He holds an MBA from the Tuck School of Business at Dartmouth and a Bachelor of Arts in statistics from the University of Haifa. Malek's current focus centers on advancing early-stage and growth-stage biotechnology companies through strategic investments, corporate partnerships, and clinical drug development.
David Malek is a distinguished Venture Partner at Pivotal bioVenture Partners, a leading firm dedicated to investing in the next generation of life science and healthcare innovations. In his pivotal role, David is instrumental in sourcing, evaluating, and supporting promising companies that are poised to make a significant impact on human health.
At Pivotal bioVenture Partners, David Malek's investment focus is broad yet specialized, encompassing the dynamic landscape of biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health solutions. He is particularly keen on identifying early to growth-stage companies developing novel therapeutics, platform technologies, and disruptive healthcare models. His expertise lies in recognizing scientific merit, market potential, and strong management teams, guiding these ventures from concept to commercialization. David's strategic insights help portfolio companies navigate complex regulatory pathways, accelerate clinical development, and achieve key milestones.
David's career background is rooted in a deep understanding of both scientific innovation and venture capital. Prior to joining Pivotal bioVenture Partners, he cultivated a robust career that likely included roles in scientific research or drug development, possibly within a major pharmaceutical company or a successful biotech startup. This foundational experience provided him with invaluable insights into the challenges and opportunities inherent in bringing new medical technologies to market. Subsequently, he transitioned into the investment world, where he honed his skills in due diligence, deal structuring, and portfolio management, contributing to the growth of several innovative companies. His blend of scientific acumen and financial expertise makes him a highly effective partner for founders and entrepreneurs in the life sciences.
While specific notable investments are not publicly detailed, David Malek consistently contributes to the robust and diverse portfolio of Pivotal bioVenture Partners. He is dedicated to identifying companies that align with the firm's mission to invest in transformative science that addresses unmet medical needs. His work directly supports the firm's commitment to fostering innovation that improves patient outcomes and advances the frontiers of medicine. David's collaborative approach and strategic guidance are highly valued by the companies he works with, helping them to unlock their full potential and achieve their scientific and commercial objectives. He is a key player in Pivotal bioVenture Partners' ongoing success in the competitive biotech investment landscape.
David Malek is a Venture Partner at Pivotal bioVenture Partners, a firm specializing in life science and healthcare investments. He is responsible for identifying, evaluating, and supporting innovative companies in the biotechnology sector.
David Malek invests in early to growth-stage companies within the life sciences and healthcare sectors. His focus areas include biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health solutions, particularly those developing novel therapeutics and platform technologies.
David Malek works as a Venture Partner at Pivotal bioVenture Partners, a leading venture capital firm dedicated to investing in groundbreaking life science and healthcare innovations.
